This Week in Peptide Research: Survodutide's Phase 3 Obesity Data, Mazdutide's US Phase 2 Trial, and a Bone-Peptide Cluster

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from August 17 through August 23, 2026. Two papers on orforglipron's ACHIEVE-J safety trial in Japan also posted this week and already received dedicated coverage in a separate article; they are not repeated here. Four threads stood out beyond that: a pair of dual-agonist obesity trials, a cluster of incretin-class meta-analyses and biomarker studies, three papers on bone-building peptides, and a basic-science finding about a mitochondrial peptide's role in the immune system.

Two dual-agonist obesity drugs posted new trial data this week. In the New England Journal of Medicine, the phase 3 SYNCHRONIZE-1 trial tested survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, in 725 adults with obesity or overweight without diabetes. Participants were randomized to once-weekly survodutide at 3.6 mg, 6.0 mg, or placebo alongside lifestyle counseling. At week 76, body weight had fallen by a mean of 12.2% in the 3.6 mg group and 13.0% in the 6.0 mg group, compared with 5.4% in the placebo group (p<0.001 for both comparisons), and 72.6% and 71.9% of the two dose groups respectively lost at least 5% of body weight versus 46.3% on placebo. Gastrointestinal side effects, mostly mild to moderate, occurred in 80.9% and 89.7% of the two survodutide groups versus 47.9% on placebo; no deaths were reported. Survodutide remains investigational, with no marketing approval from the FDA, the EMA, or Australia's TGA. Separately, in The Lancet Diabetes & Endocrinology, a phase 2 trial funded by Eli Lilly tested mazdutide, a glucagon/GLP-1 dual agonist that China's National Medical Products Administration approved in 2025 but which remains investigational in the United States, the European Union, and Australia. Across 179 participants randomized to 3-6 mg, 10 mg, or 16 mg of mazdutide or placebo, body weight fell by 7.3%, 15.6%, and 18.1% respectively at 32 weeks, versus 0.9% with placebo (p<0.0001 for all comparisons). Gastrointestinal adverse events were again the most common side effect, and treatment discontinuation for adverse events was most frequent at the 16 mg dose (20%).

Three papers this week added incretin-class comparative and safety data. A systematic review and meta-analysis in Naunyn-Schmiedeberg's Archives of Pharmacology pooled seven randomized trials (8,069 participants) of CagriSema, the fixed-dose combination of the amylin analog cagrilintide and the GLP-1 drug semaglutide. It reported that CagriSema produced significantly greater weight loss than semaglutide alone (mean difference -7.58 kg), cagrilintide alone (-9.24 kg), and placebo (-13.99 kg), all p<0.00001, with adverse events concentrated in gastrointestinal and injection-site reactions and no increase in serious adverse events; the review authors called for larger long-term trials to confirm durability. In Diabetes, Obesity & Metabolism, a post hoc analysis of two phase 2 trials of retatrutide, an investigational triple-hormone-receptor agonist from Eli Lilly, examined lipid and inflammatory biomarkers in adults with obesity, with and without type 2 diabetes. It reported reductions of up to 26.9% in non-HDL cholesterol and 24.2% in apolipoprotein B across the two trials, alongside reductions in C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in the trial that measured them, which the authors linked to lower cardiovascular disease risk. And in Diabetologia, the DIADEMA trial, a randomized, open-label study of 80 adolescents in Cairo with thalassemia-induced diabetes, a population not typically studied with incretin drugs, compared weekly dulaglutide against conventional insulin therapy over 24 weeks. Dulaglutide was associated with improved glycemic variability (a coefficient-of-variation measure that fell from 39.45% to 35.05%, versus a rise from 39.85% to 43.26% in the insulin group, p<0.001 for both changes) and lower serum ferritin, with no serious adverse events; the authors described the findings as exploratory and called for further study before any change in clinical practice.

Three papers concerned bone-building peptides, with mixed results. A systematic review and meta-analysis in the journal Spine pooled 13 studies (2,247 patients, teriparatide the primary or sole agent in nine of them) and found that perioperative anabolic osteoporosis therapy was associated with lower odds of proximal junctional kyphosis, a common mechanical complication after adult spinal deformity surgery (odds ratio 0.51), and lower odds of reoperation for mechanical failure (odds ratio 0.36); the authors rated the certainty of this evidence as low and called for randomized trials of specific agents. In Osteoporosis International, a systematic review synthesized 34 publications covering 207 patients treated with teriparatide for medication-related osteonecrosis of the jaw, a complication of long-term antiresorptive bone drugs; complete healing was reported in 163 of 201 patients with recorded outcomes and partial improvement in 24 more, but the authors described the evidence as descriptive, heterogeneous, and confounded by other treatments, stopping short of calling teriparatide an established therapy. A more rigorous test came out differently: a phase 2 randomized, placebo-controlled trial in the same journal gave abaloparatide or placebo to 48 patients with acute pelvic fracture and found no significant difference between groups in CT-based radiologic healing, pain scores, or physical performance at three months, a negative result the authors reported plainly.

In basic research, a paper in eLife reported a newly identified function for MOTS-c, a short peptide encoded not in the cell nucleus but in mitochondrial DNA. The researchers found that MOTS-c has direct antimicrobial activity against E. coli and methicillin-resistant Staphylococcus aureus, fully neutralized MRSA infection in a mouse model of peritonitis, and reprogrammed human monocytes into macrophages with altered immune signaling and improved bacterial clearance when applied during their differentiation. The authors framed this as evidence that the immune system is shaped by the mitochondrial genome as well as the nuclear genome. MOTS-c has no approved human therapeutic use and is prohibited at all times under the WADA Prohibited List. Smaller items this week included a systematic review in Aesthetic Surgery Journal of GHK-Cu, a copper-binding tripeptide with unclear regulatory status that is widely sold as a cosmetic ingredient; the review covered 20 studies, 18 of them preclinical, reporting collagen-synthesis and anti-inflammatory effects in lab models and improved patient-reported outcomes after laser resurfacing in two small clinical trials, while noting a lack of standardized clinical protocols. Two retrospective studies examined the FDA-approved somatostatin analog octreotide in different settings: a 23-patient cohort in children with congenital hyperinsulinism found long-acting octreotide achieved normal blood sugar in most patients over a mean 6 years of treatment, with gallstones and transient liver enzyme elevation as the main side effects, and a 27-patient cohort in Oman found octreotide used before surgery for catecholamine-secreting pheochromocytoma and paraganglioma was associated with significant drops in norepinephrine, blood pressure, and HbA1c. Finally, a qualitative study in the International Journal of Qualitative Studies on Health and Well-being interviewed 11 people with schizophrenia who had completed a semaglutide trial for antipsychotic-related weight gain, describing relief from what participants called "hunger pain" during treatment alongside some negative experiences of reduced appetite.

This week's papers span a wide range of evidence types: one phase 3 randomized trial, one phase 2 randomized trial, one phase 2 post hoc biomarker analysis, one small negative phase 2 trial, two meta-analyses, one pediatric randomized trial, two retrospective cohort studies, one systematic review of case-level data, one basic-science mechanistic study, and one qualitative interview study. Survodutide, cagrilintide, and retatrutide remain investigational with no FDA, EMA, or TGA approval; mazdutide is approved in China but investigational elsewhere; MOTS-c has no approved medical use anywhere and is banned by WADA; GHK-Cu's regulatory status remains unclear. As with all research covered here, these are findings a given study reported, not established clinical fact or treatment guidance.